NCT01109134

Brief Summary

The aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular perfusion and long term left ventricular infarct size, volumes and function.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 2008

Shorter than P25 for phase_3

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2009

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2009

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 22, 2010

Completed
Last Updated

April 22, 2010

Status Verified

March 1, 2010

Enrollment Period

5 months

First QC Date

April 21, 2010

Last Update Submit

April 21, 2010

Conditions

Keywords

primary angioplastytirofibanmicrocirculation

Outcome Measures

Primary Outcomes (1)

  • Indices of microvascular perfusion

    Intracoronary hemodynamic measures of index of microvascular resistance and coronary flow reserve

    Post-PCI day 4 to 5

Secondary Outcomes (6)

  • ST segment resolution

    post-PCI 90. minute

  • corrected TIMI frame count

    immediately after PCI, post-PCI day 4 to 5

  • Myocardial Blush Grade

    immediately after PCI, post-PCI day 4 to 5

  • Scintigraphic infarct size

    6th month

  • Changes in left ventricular volume

    Post-PCI day 3- 6th month

  • +1 more secondary outcomes

Study Arms (2)

Tirofiban intracoronary bolus-only

EXPERIMENTAL

Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion

Drug: tirofiban intracoronary bolus-only

Tirofiban intravenous bolus+infusion

ACTIVE COMPARATOR

Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion

Drug: tirofiban intravenous bolus plus infusion

Interventions

administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion

Also known as: Aggrastat
Tirofiban intracoronary bolus-only

administer tirofiban bolus intravenously and maintain infusion for up to 18 hours

Also known as: Aggrastat
Tirofiban intravenous bolus+infusion

Eligibility Criteria

Age25 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Typical ongoing ischemic chest pain for longer than 30 minutes
  • ST segment elevation of 0,1 mV or greater in at least two contiguous leads or a new left bundle branch block on the initial ECG.

You may not qualify if:

  • Cardiogenic shock and / or clinical instability
  • previous STEMI
  • Malignant life threatening diseases
  • Presence of an additional lesion causing more than 50% narrowing distal to the culprit lesion
  • Contraindications to aspirin, clopidogrel, or heparin
  • inability to give informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Tirofiban

Intervention Hierarchy (Ancestors)

TyrosineAmino Acids, AromaticAmino Acids, CyclicAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Cevat Kırma, Assoc.Prof

    Kosuyolu Heart and Research Hospital

    STUDY CHAIR
  • Ayhan Erkol, M.D

    Kosuyolu Heart and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 21, 2010

First Posted

April 22, 2010

Study Start

September 1, 2008

Primary Completion

February 1, 2009

Study Completion

August 1, 2009

Last Updated

April 22, 2010

Record last verified: 2010-03